KYUNG NAM PHARM plans capital increase
경남제약
053950
Signal Score
Historical Avg Return (5d)
+0.26%
Data Coverage
100%n=2473
Risk-adjusted indicator based on 2473 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Discount Rate: 25%
- • Secondary Discount Rate: 40%
- • Shareholder Subscription Period: August 3-4, 2026
- • General Public Subscription Period: August 6-7, 2026
- • Rights Issue Listing Period: July 14-21, 2026
AI Analysis Summary
KYUNG NAM PHARM.CO.,LTD. announced a decision for a paid-in capital increase. The issuance price will be determined based on a formula applying a 25% discount to the reference stock price, with a potential further discount of up to 40% under specific conditions. The capital increase aims to secure funds, but the specific purpose (e.g., facility, operating, debt repayment) is not yet disclosed. The rights issue will be listed from July 14-21, 2026, with shareholder subscriptions from August 3-4, 2026, and general public subscriptions from August 6-7, 2026. This capital increase is likely to result in significant share dilution for existing shareholders.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.